Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin plus fulvestrant versus goserelin plus anastrozole versus goserelin alone in premenopausal hormone receptor-positive metastatic breast cancer
KCT0004347Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of goserelin, fulvestrant, anastrozole in breast cancer, sponsored by Samsung Medical Center. Started Dec 2010; status: completed.
02
Drugs
goserelinfulvestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0004347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004347.